Together with the appearance of sensory-related signatures in NB tumours (C4* and C5*, Fig. 7) our “early MYCN onset” scenario reveals previously uncharted disruptions of the early sensory NC lineage, which might complement the currently prevailing model of dichotomic mesenchymal/adrenergic heterogeneity in NB11,44–46,76,89–92. The gene discussed is MYCN; the disease is neoplasm.